Cirrhosis, encephalopathy, and improved results with metabolic support.
Twenty-two patients with cirrhosis and acute encephalopathy who were refractory to medical therapy were entered into a randomized, double-blind prospective trial. This trial consisted of either neomycin or a modified amino acid solution rich in branched chains and low in aromatic amino acids and methionine (F080) in the presence of isocaloric amounts of dextrose. The groups were indistinguishable from each other by clinical or laboratory criteria; they were primarily patients who had undergone operation and they would tolerate only 30 gm of oral protein or intravenous standard amino acids. The group receiving F080 had a faster and more complete improvement in encephalopathy. This improvement correlated with the plasma molar ratio and occurred with a lower mortality rate. In addition, the patients also tolerated twice the amino acid load without encephalopathy and were in positive nitrogen balance. Modified metabolic support is effective in the setting of acute liver failure in chronic cirrhosis, particularly in patients who have undergone operation.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000596:Amino Acids / Q000097:blood; D000597:Amino Acids, Branched-Chain / Q000627:therapeutic use*; D004311:Double-Blind Method; D004569:Electroencephalography; D005260:Female; D005526:Food, Formulated; D006501:Hepatic Encephalopathy / Q000150:complications / Q000628:therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009355:Neomycin / Q000627:therapeutic use*; D011446:Prospective Studies; D011897:Random Allocation
D000596:Amino Acids; D000597:Amino Acids, Branched-Chain; D009355:Neomycin